Metus pointed out that the funding has "a bias for infectious diseases". That seems like a good criterion to add, at least when it comes to emerging diseases - diseases that haven't laid claim to many life-years yet, but might in the future. Mac made a similar point. But yeah, basically, the author nailed it.